Wave C9orf72 Trial – A multicenter, randomized, double-blind, placebo-controlled, Phase 1b/2a Study of WVE-004 administered intrathecally to patients with C9orf72-associated Amyothrophic Lateral Sclerosis (ALS) of Frontotemporal Dementia (FTD)